A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Clinical trial NCT04464798 · TERMINATED
Trial details
- NCT number
- NCT04464798
- Sponsor
- Celgene
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-11
- Primary completion
- 2023-01-31
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.